Biogen shares plummet after ending potentially groundbreaking Alzheimer's drug trial
The company said the decision to end the trial was not based on safety concerns
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biogen’s shares plummeted on Thursday after the biotechnology group announced it had ended a highly anticipated trial of Alzheimer’s drug aducanumab.
The company, which was working alongside Japan’s pharmaceutical company Eisai on the phase III-trial to study treatment for patients with Alzheimer’s, said the decision was based on an independent group’s analysis.
According to the analysis, the trials were not likely to “meet their primary endpoint”.
Biogen, one of the largest biotechs in the world, said the decision to stop the study was not based on safety concerns.
“This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” said CEO Michel Vounatsos. “We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research.
“Biogen’s history has been based on pioneering innovation, learning from successes and setbacks.”
Following the company’s announcement, which dashed hopes for sufferers of Alzheimer’s, Biogen’s stock fell more than 27 per cent in premarket trading Thursday to $234.
And the impact of the cancellation on the company’s market value could be more than $16bn, The Street estimates.
At the close of trading Wednesday, the company's market value had been $63bn.
Prior to the termination of the trial, Goldman Sachs analysts had projected sales of the drug could reach $12bn, CNBC reports.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments